Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index; none of the 63 sources its claims cite is checked for support yet.

Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic

Open access

Abstract

The translation of laboratory-scale bioprocess protocols and technologies to industrial scales and the application of human induced pluripotent stem cell (hiPSC) derivatives in clinical trials globally presents optimism for the future of stem-cell products to impact healthcare. However, while many promising therapeutic approaches are being tested in pre-clinical studies, hiPSC-derived products currently account for a small fraction of active clinical trials. The complexity and volatility of hiPSCs present several bioprocessing challenges, where the goal is to generate a sufficiently large, high-quality, homogeneous population for downstream differentiation—the derivatives of which must retain functional efficacy and meet regulatory safety criteria in application. It is argued herein that one of the major challenges currently faced in improving the robustness of routine stem-cell biomanufacturing is in utilizing continuous, meaningful assessments of molecular and cellular characteristics from process to application. This includes integrating process data with biological characteristic and functional assessment data to model the interplay between variables in the search for global optimization strategies. Coupling complete datasets with relevant computational methods will contribute significantly to model development and automation in achieving process robustness. This overarching approach is thus crucially important in realizing the potential of hiPSC biomanufacturing for transformation of regenerative medicine and the healthcare industry.

Overview

CoChat Summary

TL;DR

This roadmap argues that robust clinical translation of hiPSC-derived therapies requires integrating continuous molecular and cellular process monitoring with biological and functional assessment data to enable computational modeling, automation, and global process optimization. It highlights biological complexity, bioprocess heterogeneity, and sparse clinical trial disclosure as major barriers, noting that iPSC-derived products remain a small fraction of stem-cell clinical trials.

Key findings

  • As of August 2021, only 1.2% of documented stem-cell-derived therapeutic clinical trials in the United States utilized iPSCs, and 0.8% utilized ESCs; the vast majority of pluripotent stem cell trials involved in vitro disease modeling. The paper also cites a need for 10^6–10^12 cells per patient.
  • Clinical trial examples in Table 1 show mixed outcomes: allogeneic hESC-derived retinal pigment epithelium was Phase I complete with favorable results, whereas an autologous iPSC-derived RPE trial was halted after 2 patients due to safety concerns and copy-number variations; an iPSC-derived mesenchymal stem cell trial verified short-term safety but confounding factors obscured potential effectiveness.
  • The paper argues that process heterogeneity, genetic and epigenetic abnormalities, immunogenicity risk, somatic epigenetic memory, sex differences, and metabolic/gene-regulatory network interactions complicate iPSC manufacturing and downstream product quality.
  • It recommends coupling in-process data with multi-omics and functional characterization, and applying machine learning/computational modeling for predictive, closed-loop control of iPSC expansion and differentiation.

Methods

  • Narrative review/roadmap, not a primary experimental study; it synthesizes literature and examples to explore challenges and strategies in hiPSC biomanufacturing.
  • Uses a table of six clinical trials involving pluripotent stem-cell-derived therapeutics, listing cell type, bioprocess characteristics, manufacturing timeline, characterization strategies, and clinical outcomes/status.
  • Discusses bioprocess design considerations such as 2D static scale-out versus 3D suspension scale-up, monitoring and characterization technologies, and integration of process data with computational methods.

Limitations

  • The paper states that a lack of public disclosure in most clinical trials makes objective comparison of manufacturing design, monitoring, control, and characterization across trials “near impossible,” with details scarce even when disclosure is provided.
  • It states that no standardized requirements exist for systems and protocols despite a CGMP framework, and that minimal quality criteria exist, leading to differing process effectiveness, robustness, and outcomes.
  • The text makes evident that this is a conceptual narrative review without systematic search methods or primary data; many Table 1 entries are “not disclosed,” and the recommendations remain aspirational rather than empirically validated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41536-021-00183-7

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Considerations for clinical stem-cell manufacturing. a Ideal stem-cell population dynamics in the presence of adequate process control and intervention strategies. Maintenance of high-quality phenotype is critical in ensuring safety and efficacy in derived products. b Erosion of phenotype in the presence of inadequate process control and intervention, the result of which may take the form of genetic defects, elicitation of immune response by the host, abnormal function, cell cycle de-regulation, and tumorigenesis.
Fig. 1 Considerations for clinical stem-cell manufacturing. a Ideal stem-cell population dynamics in the presence of adequate process control and intervention strategies. Maintenance of high-quality phenotype is critical in ensuring safety and efficacy in derived products. b Erosion of phenotype in the presence of inadequate process control and intervention, the result of which may take the form of genetic defects, elicitation of immune response by the host, abnormal function, cell cycle de-regulation, and tumorigenesis.CC BY · PubMed Central
Fig. 2 Process interaction networks at a glance. Visualization of the interaction network at a high level of abstraction. Some of the critical cellular machinery dictating cell health and phenotype are shown. This machinery interacts with one another and influences from the bioprocess to continuously maintain and influence overall quality in the process population.
Fig. 2 Process interaction networks at a glance. Visualization of the interaction network at a high level of abstraction. Some of the critical cellular machinery dictating cell health and phenotype are shown. This machinery interacts with one another and influences from the bioprocess to continuously maintain and influence overall quality in the process population.CC BY · PubMed Central
Fig. 3 Complex interplay between internal regulatory processes and the influence of local environmental cues. Orchestration of phenotype is complex, depicted above in a conceptual interaction network. These interactions are illustrated to visualize the interplay between fundamental cellular processes. Ideal process control must be optimized to maintain strict homeostasis of the embryonic niche in pluripotent cell expansion bioprocessing by guiding cell network activity.
Fig. 3 Complex interplay between internal regulatory processes and the influence of local environmental cues. Orchestration of phenotype is complex, depicted above in a conceptual interaction network. These interactions are illustrated to visualize the interplay between fundamental cellular processes. Ideal process control must be optimized to maintain strict homeostasis of the embryonic niche in pluripotent cell expansion bioprocessing by guiding cell network activity.CC BY · PubMed Central
Fig. 4 Overview of several important components and characteristics in bioprocess design, development, and optimization. Considerations must be made for the infrastructure and technology used to monitor, control, and intervene in the process. These considerations must be integrated with those made for characterization of the cell population to build a complete model for artificial manipulation of phenotype to ensure safety and efficacy downstream of expansion.
Fig. 4 Overview of several important components and characteristics in bioprocess design, development, and optimization. Considerations must be made for the infrastructure and technology used to monitor, control, and intervene in the process. These considerations must be integrated with those made for characterization of the cell population to build a complete model for artificial manipulation of phenotype to ensure safety and efficacy downstream of expansion.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 2 Not valid · 38 Not checked · 17 Own results and interpretations

19 more claims

Create a free account to see all 57 claims and to verify the 63 references still open.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Citations

Cites

Show all 108 references

Research works printed but not linked: 1

  1. Lavon, N., Zimerman, M. & Itskovitz-Eldor, J. In Advances in Biochemical Engineering/Biotechnology Book Series, ABE 163, 22–37 (2017). Edited by Scheper, T., Zhong, J. Published by Springer-Verlag Berlin Heidelberg NewYork.

Cited by

See all 33

Metadata

Authors
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S.
Affiliations
University of Calgary (CA)
Corresponding author
Kallos, Michael Scott
Venue
npj Regenerative Medicine
Published
2021-11-01
Volume
6
Issue
1
Pages
72-72
ISSN
2057-3995 (ISSN-L)
OpenAlex
W3210153660
Cited by
33
References
108
Citations by year
2026: 8 · 2025: 5 · 2024: 7 · 2023: 7 · 2022: 5 · 2021: 1
FWCI
0.51
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Regenerative Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Gouvernement du Canada | Canadian Institutes of Health Research
  • Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
  • Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
human induced pluripotent stem cells, bioprocess scale-up, process optimization, process analytical technology, process modeling, process robustness, clinical translation, regenerative medicine, bioprocess automation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic. https://app.cochat.ai/papers/10.1038/s41536-021-00183-7
The paper
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021). Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic. npj Regenerative Medicine. https://doi.org/10.1038/s41536-021-00183-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.